Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.46 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.44 |
| ▸ | IKZF1 | Q13422 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705705 | 0.83 | CRBN (0.46) | CRBNDDB1IKZF2IKZF1 | |
| Formic Acid SCHEMBL23705704 | 0.81 | BRD9 (0.53) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL22291517 | 0.81 | BRD9 (0.55) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL31411091 | 0.79 | CRBN (0.55) | CRBNDDB1IKZF2IKZF1ALDH1A1 | |
| SCHEMBL23729603 | 0.77 | CRBN (0.47) | CRBNDDB1IKZF2ALDH1A1CHRM2 | |
| SCHEMBL19503590 | 0.74 | CRBN (0.65) | CRBNDDB1IKZF2IKZF1ALDH1A1 | |
| SCHEMBL29617032 | 0.73 | CRBN (0.65) | CRBNDDB1IKZF2IKZF1ALDH1A1 | |
| SCHEMBL23705654 | 0.73 | CRBN (0.65) | CRBNDDB1IKZF2IKZF1ALDH1A1 | |
| SCHEMBL19475485 | 0.71 | CRBN (0.62) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Hydrochloric Acid SCHEMBL31307049 | 0.71 | CRBN (0.62) | CRBNDDB1IKZF2IKZF1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |